64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer (AMPLIFY)

Clarity Pharmaceuticals

Status and phase: Not yet enrolling; Phase 3

Conditions: Prostate Cancer Patients Who Have Brachytherapy Seed Implant; Prostate Cancer Patients Treated by Radiotherapy; Cryotherapy; Prostate Cancer Recurrent; Prostate Cancer Patients With Detectable PSA Following Prostatectomy; Prostate Cancer

Treatments: Drug: 64Cu-SAR-bisPSMA

Study type: Interventional

Funder types: Industry

Identifiers

NCT06970847

CLP10

Details and patient eligibility

About

The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer

Enrollment: 220 estimated patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. At least 18 years of age.

2. Signed informed consent.

3. Life expectancy ≥ 6 months as determined by the Investigator.

4. Histologically confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy.

5. Participant potentially eligible for salvage therapy with curative intent.

6. PSA level after definitive therapy:

   1. Post-radical prostatectomy: Detectable or rising PSA that is ≥ 0.2 ng/mL with a confirmatory PSA ≥ 0.2 ng/mL (per AUA recommendation) or
   2. Post-radiation therapy, cryotherapy, or brachytherapy: Increase in PSA level that is elevated by ≥ 2 ng/mL above the nadir (per ASTRO-Phoenix consensus definition).

7. Participant willing to undergo biopsy of a 64Cu-SAR-bisPSMA PET-positive lesion for histological confirmation of PC, where this is safe and feasible.

8. An Eastern Cooperative Oncology performance status of 0-2.

Exclusion criteria

1. Participants who received investigational agent within 5 biological half-lives prior to Day 1.
2. Participants administered any high energy (>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1.
3. Previous systemic therapy for PC (with the exception of neoadjuvant and adjuvant systemic therapy as part of the definitive therapy).
4. Ongoing treatment or treatment within 6 months of Day 1 with any systemic therapy (e.g. any investigational therapy, androgen-deprivation therapy, antiandrogen, gonadotropin-releasing hormone, luteinizing hormone-releasing hormone agonist or antagonist, chemotherapy, immunotherapy or radiotherapy) for PC.
5. Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components.
6. Any serious medical condition or extenuating circumstance (including receiving the investigational product or not capable of having a PET scan) which the investigator feels may interfere with the procedures or evaluations of the study.

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

220 participants in 1 patient group

64Cu-SAR-bisPSMA 200MBq 64Cu-SAR-bisPSMA.

Experimental group

Treatment:

Drug: 64Cu-SAR-bisPSMA